We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...

The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Novo Nordisk NVO has outperformed the market over the past 10 years by 6.26% on an annualized basis producing an average ...

In a report released on October 15, David Evans from Kepler Capital maintained a Hold rating on Novo Nordisk (0QIU – Research Report), ...

Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give ...

Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...

The general mood among these heavyweight investors is divided, with 45% leaning bullish and 50% bearish. Among these notable ...

One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...

Bagsværd, Denmark, 14 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and ...